These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32628427)

  • 1. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
    Chiang CE; Ueng KC; Chao TH; Lin TH; Wu YJ; Wang KL; Sung SH; Yeh HI; Li YH; Liu PY; Chang KC; Shyu KG; Huang JL; Tsai CD; Hung HF; Liu ME; Chao TF; Cheng SM; Cheng HM; Chu PH; Yin WH; Wu YW; Chen WJ; Lai WT; Lin SJ; Yeh SJ; Hwang JJ
    J Chin Med Assoc; 2020 Jul; 83(7):587-621. PubMed ID: 32628427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
    Chiang CE; Lin SY; Lin TH; Wang TD; Yeh HI; Chen JF; Tsai CT; Hung YJ; Li YH; Liu PY; Chang KC; Wang KL; Chao TH; Shyu KG; Yang WS; Ueng KC; Chu PH; Yin WH; Wu YW; Cheng HM; Shin SJ; Huang CN; Chuang LM; Lin SJ; Yeh SJ; Sheu WH; Lin JL
    J Chin Med Assoc; 2018 Mar; 81(3):189-222. PubMed ID: 29453020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.
    Chiang CE; Wang TD; Ueng KC; Lin TH; Yeh HI; Chen CY; Wu YJ; Tsai WC; Chao TH; Chen CH; Chu PH; Chao CL; Liu PY; Sung SH; Cheng HM; Wang KL; Li YH; Chiang FT; Chen JH; Chen WJ; Yeh SJ; Lin SJ
    J Chin Med Assoc; 2015 Jan; 78(1):1-47. PubMed ID: 25547819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
    Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
    Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of metformin in diseases of aging.
    Miles JM; Rule AD; Borlaug BA
    Curr Diab Rep; 2014 Jun; 14(6):490. PubMed ID: 24752835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes.
    Chiang CE; Ueng KC; Chao TH; Lin TH; Wu YJ; Wang KL; Sung SH; Yeh HI; Li YH; Liu PY; Chang KC; Shyu KG; Huang JL; Tsai CD; Hung HF; Liu ME; Chao TF; Cheng SM; Cheng HM; Chu PH; Yin WH; Wu YW; Chen WJ; Lai WT; Lin SJ; Yeh SJ; Hwang JJ; Hou CJ
    JACC Asia; 2021 Sep; 1(2):129-146. PubMed ID: 36338159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.